glp-1 obesity drug news Only one in 12 remain on a for at three years The Impact of GLP-1 on

In comparison, while half (51 %) of U.S

Although wholesalers are confirming that GLP-1 therapies are back in stock, many pharmacies have still not received stock or are simply unable to maintain adequate stock levels due to the uncertainty of the supply chain

The benefits of being at a healthy weight are substantial, with one study published in January suggesting weight-loss jabs could reduce the risk of 42 diseases including heart disease, cancer, clotting disorders, Alzheimers, chronic kidney disease, addiction and a range of psychiatric conditions

Understanding this mechanism helps individuals and healthcare providers address constipation associated with GLP-1 therapies more effectively, tailoring interventions to support digestive health during the weight loss journey

It is usually not painful but can be bothersome